Department of Urology, Korea University Hospital, Korea University, College of Medicine, Seoul, Korea.
Int J Clin Pract. 2012 Dec;66(12):1209-15. doi: 10.1111/j.1742-1241.2012.02985.x.
To evaluate the efficacy and treatment satisfaction with low-dose (0.2 mg) tamsulosin in patients with symptomatic benign prostatic hyperplasia (BPH), and to investigate individual lower urinary tract symptoms according to treatment satisfaction.
A cross-sectional study was conducted in a total sample of 2574 patients from multiple centres. International Prostate Symptom Score (IPSS), prostate volume, uroflowmetry and combined medications were reviewed. Detailed questionnaires were used to assess treatment satisfaction and IPSS 8 weeks after treatment with low-dose tamsulosin.
After 8 weeks of treatment with low-dose tamsulosin, IPSS improved significantly. Among the 2574 patients, 1,630 (63.42%) were satisfied and 940 patients (36.50%) were dissatisfied with low-dose tamsulosin. The reasons for dissatisfaction included efficacy problems (84.66%) and side effects (3.72%). Treatment satisfaction was affected by symptom duration, baseline IPSS, and prostate size (p = 0.0441, < 0.001, < 0.009, respectively). IPSS voiding (IPSS-V) and IPSS storage (IPSS-S) after treatment differed significantly depending on the degree of satisfaction (p < 0.001). IPSS-V after treatment did not improve in patients who were 'not satisfied' or 'totally not satisfied' (p = 0.170, 0.240, respectively). All the individual IPSS items except urgency (p = 0.1436) varied significantly with the degree of satisfaction (p < 0.001).
Treating symptomatic BPH with low-dose tamsulosin improved IPSS, but more than one-third of patients were dissatisfied with the treatment. The main reason for dissatisfaction was efficacy problems, and the degree of satisfaction was related to symptom duration, baseline IPSS, and prostate size, and also to IPSS-V. In patients with severe LUTS, the tamsulosin dose should be increased earlier.
评估低剂量（0.2 毫克）坦索罗辛治疗有症状的良性前列腺增生（BPH）患者的疗效和治疗满意度，并根据治疗满意度调查个体下尿路症状。
对来自多个中心的 2574 例患者进行了一项横断面研究。回顾国际前列腺症状评分（IPSS）、前列腺体积、尿流率和联合用药情况。使用详细的问卷评估低剂量坦索罗辛治疗 8 周后的治疗满意度和 IPSS。
低剂量坦索罗辛治疗 8 周后，IPSS 显著改善。在 2574 例患者中，1630 例（63.42%）对低剂量坦索罗辛满意，940 例（36.50%）不满意。不满意的原因包括疗效问题（84.66%）和副作用（3.72%）。治疗满意度受症状持续时间、基线 IPSS 和前列腺大小的影响（p=0.0441，<0.001，<0.009）。治疗后 IPSS 排尿（IPSS-V）和 IPSS 存储（IPSS-S）的满意度明显不同（p<0.001）。在“不满意”或“完全不满意”的患者中，治疗后 IPSS-V 并未改善（p=0.170，0.240）。除急迫性外（p=0.1436），所有个体 IPSS 项目均与满意度显著相关（p<0.001）。
低剂量坦索罗辛治疗有症状的 BPH 可改善 IPSS，但超过三分之一的患者对治疗不满意。不满意的主要原因是疗效问题，满意度与症状持续时间、基线 IPSS 和前列腺大小有关，也与 IPSS-V 有关。在严重的 LUTS 患者中，应更早增加坦索罗辛剂量。
